November 18, 2011, Stevensville, Maryland – Vapotherm, a privately held manufacturer of respiratory care devices for hospital and home use, announced today that the Precision Flow® system validated by Ikaria, Inc. and cleared by the FDA for the administration of nitric oxide via high flow nasal cannula is now available. The Nitric Oxide Adapter product is part of Vapotherm’s High Flow Specialty Gas Program for optimal conditioning of breathing gases.
Vapotherm’s High Flow Specialty Gas Program was created to expand High Flow Therapy (HFT®) beyond air and oxygen to other medical and specialty gases. The Company’s flagship platform device, the Precision Flow®, was developed with a modular design concept to allow for several specialty applications in neonatal, pediatric and adult patient populations. In all applications, the device optimizes the delivery of gases via precise blending, flow control and temperature management. As with all Vapotherm HFT® products, the overall goal is non-invasive respiratory support via simple nasal cannula in a device that is easy for clinicians to operate but comprehensive in terms of safety and performance features.
Vapotherm, Inc. is a privately held manufacturer of respiratory care devices for hospitals and home care use based in Stevensville, Maryland. The Company is dedicated to the development of innovative, noninvasive technologies for respiratory therapy, especially for the treatment of chronic lung and acute breathing disorders. For more information, visit www.vapotherm.com.